2016
Press/Media Releases:
OPKO Announces U.S. Launch of RAYALDEE™
November 23, 2016
OPKO Presents Data on RAYALDEE® at ASN Kidney Week 2016
November 17, 2016
FDA Approves New Drug Application for RAYALDEE® to Treat Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Stage 3-4 Chronic Kidney Disease
June 21, 2016
OPKO Announces Appointment of Douglass Laidlaw as Vice President of Medical Affairs
May 11, 2016
OPKO Announces Appointment of Thomas Nusbickel as Senior Vice President of Pharmaceutical Marketing and Market Access
May 10, 2016
Vifor Fresenius Medical Care Renal Pharma and OPKO Health Enter into Agreement for OPKO's RAYALDEE®
May 9, 2016
OPKO Health Reports First Quarter Financial and Operating Results
May 9, 2016
OPKO Presents Additional Data on RAYALDEE® at National Kidney Foundation Spring Clinical Meetings 2016
April 28, 2016
FDA Accepts Resubmission of New Drug Application for RAYALDEE®
April 27, 2016
OPKO Announces Appointment of James DeMarco as Senior Vice President of Pharmaceutical Sales
April 25, 2016
OPKO Presents Additional Data on RAYALDEE® at ENDO 2016
April 1, 2016
OPKO Presents Additional Data on RAYALDEE® to Treat Secondary Hyperparathyroidism in Chronic Kidney Disease
March 30, 2016
OPKO Receives Complete Response Letter from FDA for RAYALDEE® New Drug Application
March 30, 2016 |
